TVM Capital Life Science

🌟 Congratulations to Dr. Valentina Agostoni and Philipp Lechner on their well-deserved promotions to Principal at TVM Capital Life Science! 🌟 Since joining TVM in 2020, both Valentina and Philipp have made invaluable contributions, and their team is thrilled to recognize their hard work and dedication with this new role. Dr. Valentina Agostoni has been instrumental in advancing our portfolio in preclinical drug development. With hands-on experience spanning hit identification to IND-enabling studies, she draws on her six years of experience as a Preclinical Development Scientist in dynamic startups. Valentina’s academic foundation as a Ph.D. in Biopharmacy from the University of Paris-Saclay complements her deep expertise in the field. Philipp Lechner has contributed significantly with his sharp financial acumen and insights into life science VC investing. Before joining TVM, Philipp honed his skills in corporate & investment banking, where he worked on cross-border M&A transactions across healthcare industries. He holds a Master’s degree in International Finance and Economics from the Nuremberg Institute of Technology. Even before officially joining TVM, Philipp collaborated with us during his master thesis, analyzing financial decision-making in LSI I investments. It’s a privilege to work alongside such talented professionals. Here’s to continued success and innovation at TVM! 🚀 #TeamTVM #LifeSciences #Innovation #VentureCapital #Promotions #Congratulations

🎉 Congratulations to Egg Medical, a TVM Capital Life Science portfolio company, on their strategic alliance with BIOTRONIK! This partnership marks a significant step forward in improving radiation protection for interventional healthcare workers across the U.S.   With EggNest™ Radiation Protection Systems reducing radiation exposure by up to 99%, this collaboration will help create safer working environments in EP and Cath labs.   Exciting times ahead for Egg Medical as they expand their impact in the healthcare industry! 👏   #RadiationProtection #HealthcareInnovation #MedTech https://lnkd.in/ezSjRmRK

TVM Capital Life Science extends its 🎉 congratulations 🎉 to our portfolio company, Panthera Dental, on their collaboration with Amann Girrbach!   By combining cutting-edge technologies, they are setting a new standard in dental CAD/CAM solutions for All-on-X restorations.   With the award-winning Panthera Fusion Bar™ (PFB) now seamlessly integrated into the Ceramill workflow, dental professionals can achieve unparalleled precision, efficiency, and quality—while skipping the complexities of milling titanium. This partnership ensures a validated and synchronized workflow, giving clinicians more flexibility and confidence in delivering top-tier patient care.   We are proud to support Panthera Dental as they continue to innovate and expand their impact in the dental technology and medical device industry!   #DentalInnovation #AllOnX #CADCAM #DentalTechnology #Partnerships   https://lnkd.in/ef_EA45b

🌟 Join us for J.P. Morgan Healthcare Week! 🌟 From January 13–16, 2025, TVM Capital Life Science will be in San Francisco for the premier event in healthcare investment. Dr. Luc Marengere and Marc Rivière will represent our team, engaging with innovative companies and the investment community shaping the future of healthcare. 🌐💡 📍 Let’s meet! We’d love to connect during JPM2025 to explore opportunities and discuss how we can drive innovation together. 💬 #Investment #Innovation #LifeScience #VentureCapital #JPMorgan

Happy Holidays from all of us at TVM Capital Life Science! ✨   As we reflect on a year of progress and innovation, we look ahead to 2025 with excitement for continued growth, impactful connections, and shared success.   Wishing you a joyful holiday season and a prosperous new year! ✨

🚀 Artificial Intelligence in Drug Research between Vision and Reality TVM Capital Life Science is pleased to be featured in the latest Plattform Life Sciences article, exploring how artificial intelligence is reshaping the life science sector. Artificial intelligence is rapidly revolutionizing drug development. At the recent EBD Group #BIOEurope in Stockholm, this topic took center stage, highlighting how AI-driven innovation could redefine success in pharmaceutical research. The applications of AI in the sector are expanding rapidly, from clinical decision-making to high-throughput screening. By identifying failure risks earlier, AI not only saves valuable time and resources but also points to a future where research is faster, more efficient, and far more cost-effective. For venture capital investors, the implications are clear: AI holds immense potential to improve returns by accelerating timelines, reducing costs, and boosting efficiency across the pipeline. The question is no longer if AI will transform drug discovery but rather how fast and to what extent this revolution will deliver results. Find out more about how AI is shaping the Future of the Life Science Sector and which Biotech companies are already utilizing AI for their drug development here: https://lnkd.in/ef6MrcJ3 Envisagenics (Maria Luisa Pineda, PhD.) Exscientia (Nikolaus Krall) Insilico Medicine (Michelle Chen) Molecular Health (Stephan Brock)

🌟 AI will lead us to a bold and bright future🌟 At this year’s BIO-Europe in Stockholm, TVM Capital Life Science was thrilled to explore how AI is transforming drug discovery, development, and diagnostics. From a compelling keynote by Verena Schustereder from Google Europe to thought-provoking panels on AI's potential to reduce costs, improve efficiency, and tackle high failure rates in drug development, the discussions were certainly thought provoking! 🔬 Key takeaways: AI's power to analyze vast datasets, from genomics to clinical trials, is enabling faster and more precise drug discovery. In diagnostics, AI is helping physicians diagnose diseases faster and guide patients to the right therapies. The life sciences industry is embracing AI as a solution to the complexity of biologic systems and as a tool to improve pharma productivity. 💡 As one speaker highlighted: "AI is definitely the future for biotech and biopharma—those who don't embrace it may be left behind." A huge thank you to the moderators, panelists, and EBD Group for making this such a valuable event. Watch our highlights video to catch the latest insights and see where AI is taking the life sciences industry! Thank you! Envisagenics (Maria Luisa Pineda, PhD.), Exscientia (Nikolaus Krall), Insilico Medicine (Michelle Chen), Owkin (Denis Dubuy), Vektor Medical, Inc. (David Krummen) #BIOEurope #ArtificialIntelligence #LifeSciences #DrugDiscovery #Diagnostics

💡Was treibt Visionäre an? 🤔    Private Equity und Venture Capital sind zentrale Treiber der wirtschaftlichen Transformation in Deutschland. Auch TVM Capital Life Sciences investiert hierzulande Wagniskapital in differenzierte Ansätze, damit Patienten Zugang zu Innovationen erhalten. Zwei aktuelle Beispiele aus diesem Jahr:   Smart Reporting GmbH aus München: Ein Vorreiter und Marktführer im Bereich der medizinischen Befundung, insbesondere in der Radiologie und Pathologie. Die medizinische Dokumentationstechnologie wird bereits von Tausenden von Ärztinnen und Ärzten auf der ganzen Welt genutzt. TVM führte als Lead-Investor die Series-C-Finanzierungsrunde in Höhe von 23 Millionen Euro an.    myo aus Berlin: Erste SaaS-Lösung mit der Mission, die Kommunikation in der Altenpflege durch Digitalisierung zu revolutionieren. Bereits über 350 Einrichtungen, ihre Bewohner, Angehörigen und Dienstleister profitieren davon. TVM führte die Series-A-Finanzierungsrunde mit einem Investment von 8 Millionen Euro an.   *** TVM Capital Life Sciences supports the campaign of BVK e.V., the German Private Equity and Venture Capital Association, to raise awareness of the decisive role that venture capital and other equity investments are playing in the economic transformation of Germany. 🌍🚀    https://lnkd.in/dKKFWW6y #HealthcareInnovations #HealthTech #VentureCapital #InvestmentStrategy #BVK

📈 A strong year for German biotech investments! The German biotech ecosystem is experiencing a notable recovery, with €800 million in venture capital flowing into the sector in the first nine months of 2024—the highest increase in years. TVM Capital Life Science is proud to see such momentum driving innovation and creating opportunities for groundbreaking therapies. This underscores the growing confidence in German biotech and its potential to deliver transformative solutions in healthcare. 🚀 Read more on the topic in today’s Handelsblatt article from Maike Telgheder (German): https://lnkd.in/d7rPEwDm #Biotech #VentureCapital #Innovation

🚀 TVM Capital Life Science Spotlight at BIO-Europe 2024: Pioneering AI in Drug Development and Diagnostics 🌍 TVM is pleased to be featured in two insightful articles by independent journalist Cormac Sheridan, published by EBD Group from BIO-Europe 2024. These articles showcase the transformative conversations the @TVM hosted panels sparked around artificial intelligence (AI) in drug development and diagnostics. The panel: "AI in Drug Development: Dreams and Realities," explored both the vast potential and the sober actuality of AI in advancing drug discovery. Key takeaways: - Early failure recognition: AI tools may save time and resources by identifying failure risks earlier. - Human insight still essential: While AI has the potential to accelerate processes, human intelligence remains crucial for interpreting complex biological data. - New paradigms in discovery: From focused screening campaigns to RNA-based biomarkers, AI has the potential to rewrite the rulebook for drug discovery. The article "Biotech Partnering a Constant Amid Industry Uncertainty," spotlighted the power of new technologies, including AI, in drug discovery and development as well as diagnostics. As TVM Managing Partner Hubert Birner highlighted, AI could become an important tool to improve overall success rates for drug development and diagnostics. 💡 At TVM Capital Life Science, we believe AI is not just a tool but, when wielded correctly, has the potential to be a catalyst for better patient care. Read the full articles here: https://lnkd.in/ebddWiZG and https://lnkd.in/exnErAZt #BIOEurope2024 #ArtificialIntelligence #DrugDevelopment #Diagnostics #Innovation #LifeSciences